National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

    Search  
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Restructuring the NCI Clinical Trials Enterprise

Clinical Trials Reporting Program

Coordinating Center for Clinical Trials

States Requiring Coverage of Clinical Trial Costs
Related Pages
Melanoma Home Page
NCI's gateway for information about melanoma.

Search for Clinical Trials
NCI's PDQ® Cancer Clinical Trials Registry.
Melanoma Trial Results
6.  Interferon Superior to a GMK Vaccine in Preventing Melanoma Relapse
(Posted: 05/04/2001, Reviewed: 05/25/2005) - High-dose interferon proved superior to a GMK ganglioside vaccine, a potentially promising cancer therapy, in protecting high-risk patients against a recurrence of their melanoma, according to research from a multicenter clinical trial published in the May 1, 2001, Journal of Clinical Oncology.

7.  High-Dose Interferon Prolongs Time to Recurrence in Melanoma
(Posted: 02/20/2001, Reviewed: 03/23/2005) - High-dose interferon alfa-2b significantly prolongs the time before melanoma recurs compared to low-dose interferon or no therapy, according to the findings of a large, randomized clinical trial.

8.  Chemoimmunotherapy No Better Than Combination Chemotherapy Alone for Metastatic Melanoma
(Posted: 11/10/1999, Reviewed: 03/23/2005) - A prospective randomized clinical trial at the National Cancer Institute finds that aggressive treatment for metastatic melanoma that combines chemotherapy drugs with immunotherapy agents yields survival results no better than that of treatment with combination chemotherapy alone.
< Previous  1 2 

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov